Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026

Same author

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Lancet (London, England)·2026

Same author

Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.

Transplantation and cellular therapy·2026

Same author

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Blood·2026

Same author

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.

The Lancet. Oncology·2026

Same author

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Expert review of hematology·2025

Search research articles

Related Experiment Video

Updated: Jul 9, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Chimeric antigen receptor T-cell therapy.

Cale Burge^1,2, Vinay Vanguru^1,2, Phoebe Joy Ho^1,2

¹Royal Prince Alfred Hospital, Sydney.

Australian Prescriber

|December 6, 2023

Summary

Chimeric antigen receptor T-cell therapies offer new hope for certain blood cancers, improving remission rates. While effective, potential complications like cytokine release syndrome and neurotoxicity require careful management.

Keywords:

B-cell lymphoma acute lymphoblastic leukaemia axicabtagene ciloleucel chimeric antigen receptor tisagenlecleucel

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Jul 9, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in treating hematologic malignancies.
CAR T-cells are genetically engineered lymphocytes designed to enhance the host immune system's ability to target cancer cells.

Purpose of the Study:

To review the efficacy and safety of CAR T-cell therapies for relapsed or refractory diffuse large B-cell lymphoma and acute lymphoblastic leukaemia.
To discuss the potential of CAR T-cell therapies in other hematologic and solid organ malignancies.

Main Methods:

Patient-derived T-cells are harvested, genetically modified to express CARs, expanded ex vivo, and reinfused.
The study involves a review of existing clinical data and outcomes.

Main Results:

CAR T-cell therapy demonstrates increased complete response rates and potential for long-term remission in specific B-cell lymphomas and leukaemias.
Early-phase studies show promise in other cancers, including mantle cell lymphoma, multiple myeloma, and glioblastoma multiforme.

Conclusions:

CAR T-cell therapy is a promising treatment modality for relapsed/refractory B-cell malignancies, offering improved outcomes.
Management of short-term toxicities, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, is critical for patient safety.